Bone News and Research

RSS

ARIAD Pharmaceuticals' investigational pan-BCR-ABL inhibitor receives FDA and EMA orphan drug designation

ARIAD Pharmaceuticals, Inc. today announced that its investigational pan-BCR-ABL inhibitor, AP24534, has been granted orphan drug designation by both the U. S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA). In the U.S., the orphan designation of AP24534 is for the treatment of chronic myeloid leukemia (CML) and Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL) and in the E.U., its orphan designation is for CML and acute lymphoblastic leukemia.

2 Mar 2010

Aprepitant drug can reduce nausea and vomiting when combined with other anti-nausea drugs

Bone marrow transplant patients say two of the most debilitating side effects of the treatment are nausea and vomiting caused by chemotherapy and radiation.

1 Mar 2010

Precise immune disturbances leading to Coeliac disease: More insight

New research has identified four aspects of immune system disturbance which lead to the development of coeliac disease. Nearly 40 different inherited risk factors which predispose to the disease have now been identified. These latest findings could speed the way towards improved diagnostics and treatments for the autoimmune complaint that affects 1 in 100 of the population, and lead to insights into related conditions such as type 1 diabetes.

28 Feb 2010

Unexplained, sudden anemia: Brown recluse spider bite

As spring approaches and people return to outdoor activities, caution should be taken in areas of the country that are home to Loxosceles reclusa, also called the brown recluse spider. A new study from St. Jude Children's Research Hospital found that when patients present with sudden anemia, but the cause is elusive, the brown recluse spider should be part of the differential diagnosis, at least in parts of the nation where the spider is regularly found.

27 Feb 2010

Body repairs itself through microvesicles: New hope for tissue regeneration

Researchers at Rhode Island Hospital have discovered how cells communicate with each other during times of cellular injury. The findings shed new light on how the body repairs itself when organs become diseased, through small particles known as microvesicles, and offers hope for tissue regeneration.

27 Feb 2010

"Smart Hip": Non-evasive method to regenerate bone tissue

To monitor the real-time performance of bone implants is the challenge of "Smart Hip", an innovative medical device that aims to reduce the number of surgical interventions in the hip area and regenerate bone tissue by using non-evasive methods. The concept's validation - unique in the world and developed by a PHD from the Faculty of Engineering of the University of Porto -, has already been successfully tested on animals.

27 Feb 2010

UAMS researchers identify age-related mechanism as primary cause of osteoporosis

Marking a shift in decades of thought on the cause of osteoporosis, researchers at the University of Arkansas for Medical Sciences have identified an age-related mechanism - not a decrease of the hormone estrogen - as the primary culprit.

27 Feb 2010

Shire receives marketing approval from FDA for VPRIV

Shire plc, the global specialty biopharmaceutical company, announced today that the U.S. Food and Drug Administration has granted marketing approval for VPRIV, a human cell line derived enzyme replacement therapy (ERT) for the long-term treatment of Type 1 Gaucher disease in pediatric and adult patients.

27 Feb 2010

Gaucher disease: FDA approves VPRIV

The U.S. Food and Drug Administration has approved velaglucerase alfa for injection (VPRIV) to treat children and adults with a form of the rare genetic disorder Gaucher disease.

26 Feb 2010

Rare Disease Day 2010: Alexion Pharmaceuticals joins NORD and EURORDIS to raise awareness

Alexion Pharmaceuticals, Inc., has joined the National Organization for Rare Disorders (NORD) and the European Organization for Rare Diseases (EURORDIS) in supporting the goals of the third annual Rare Disease Day, February 28, 2010.

26 Feb 2010

Salmonella-infected mice help understand how symptoms of HLH develop

A new University of Colorado at Boulder study shows mice infected with the bacteria salmonella develop clinical signs consistent with a deadly and poorly understood human inflammatory disease, a finding that may lead to new therapies.

26 Feb 2010

$Fragility fractures: 'Own the Bone' program for enhancing prevention and treatment$

Fragility fractures: 'Own the Bone' program for enhancing prevention and treatment

As many as half of all women and a quarter of men over the age of 50 can expect to sustain a fractured bone related to osteoporosis or low bone density. To enhance prevention and treatment of these fragility fractures, NewYork-Presbyterian Hospital/Columbia University Medical Center has implemented an innovative program called Own the Bone™ developed by the American Orthopaedic Association.

26 Feb 2010

Genoptix to participate in Aetna's national provider network to offer laboratory and diagnostic services

Genoptix, Inc. today announced that it will participate in Aetna's (AET) national provider network to offer specialized laboratory and comprehensive diagnostic services designed to optimize the care of patients suffering from hematomalignancies, or cancers of the blood and bone marrow, including leukemia and lymphoma.

26 Feb 2010

RF Kyphoplasty procedure using StabiliT Vertebral Augmentation System: DFine treats over 2000 patients

DFine, Inc., a developer of minimally invasive solutions for treating vertebral compression fractures, announced today that over 2,000 patients with over 3000 fractures have been treated globally with the RF Kyphoplasty procedure using the StabiliT® Vertebral Augmentation System.

26 Feb 2010

Avoiding dairy products due to lactose intolerance may pose diet and health risks, say experts

People may avoid milk and other dairy products due to concerns about lactose intolerance, but eliminating these nutrient-rich foods may not only be unnecessary to manage the condition - it could impact diet and health, concludes a panel of experts assembled by the National Institutes of Health (NIH).

26 Feb 2010

Genta initiates new dose-ranging study of tesetaxel drug

Genta Incorporated announced that the Company has initiated a new dose-ranging study of tesetaxel, the Company’s novel oral tubulin inhibitor, using a weekly dosing regimen. Tesetaxel -- a late Phase 2 oncology product -- is the leading oral taxane currently in clinical development.

26 Feb 2010

Kinex Pharmaceuticals announces KX2-391 Phase 2 safety and efficacy clinical trial in men with CRPC

Kinex Pharmaceuticals opened a Phase 2 clinical trial to evaluate the safety and efficacy of KX2-391 in patients with bone-metastatic, castrate-resistant prostate cancer (CRPC) who have not had prior chemotherapy.

25 Feb 2010

CHOP and AIAM collaborate to develop more accurate child crash test dummies

A research report released today by The Children's Hospital of Philadelphia (CHOP) and the Association of International Automobile Manufacturers, Inc. (AIAM) details CHOP's cutting-edge work with academic and industry collaborators to develop more accurate child crash test dummies, called child anthropometric test devices (ATD's).

25 Feb 2010

Study demonstrates Prochymal treamtent is safe for cardiac patients

“Patients receiving Prochymal did better than those receiving only standard-of-care,” said Dr. Hare, lead author of the JACC publication.

25 Feb 2010

Translational Regenerative Medicine Forum in Winston-Salem

A spray-on skin product and an injectable cell therapy for heart attack patients are among 17 regenerative medicine technologies that will be showcased during the Translational Regenerative Medicine Forum, set for April 6-8 in Winston-Salem.

25 Feb 2010

Bone News and Research

ARIAD Pharmaceuticals' investigational pan-BCR-ABL inhibitor receives FDA and EMA orphan drug designation

Aprepitant drug can reduce nausea and vomiting when combined with other anti-nausea drugs

Precise immune disturbances leading to Coeliac disease: More insight

Unexplained, sudden anemia: Brown recluse spider bite

Body repairs itself through microvesicles: New hope for tissue regeneration

"Smart Hip": Non-evasive method to regenerate bone tissue

UAMS researchers identify age-related mechanism as primary cause of osteoporosis

Shire receives marketing approval from FDA for VPRIV

Gaucher disease: FDA approves VPRIV

Rare Disease Day 2010: Alexion Pharmaceuticals joins NORD and EURORDIS to raise awareness

Salmonella-infected mice help understand how symptoms of HLH develop

Fragility fractures: 'Own the Bone' program for enhancing prevention and treatment

Genoptix to participate in Aetna's national provider network to offer laboratory and diagnostic services

RF Kyphoplasty procedure using StabiliT Vertebral Augmentation System: DFine treats over 2000 patients

Avoiding dairy products due to lactose intolerance may pose diet and health risks, say experts

Genta initiates new dose-ranging study of tesetaxel drug

Kinex Pharmaceuticals announces KX2-391 Phase 2 safety and efficacy clinical trial in men with CRPC

CHOP and AIAM collaborate to develop more accurate child crash test dummies

Study demonstrates Prochymal treamtent is safe for cardiac patients

Translational Regenerative Medicine Forum in Winston-Salem

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Latest News